PVAC Sets Dec 9 Vote on Tigerless Health De-SPAC; Target Misses Projections Badly
CMCAF has more than doubled off its 52-week low of $2.6.
Summary
A December 9, 2026 vote on merging with Tigerless Health is set by PVAC's definitive proxy, and the target is a money-losing insurtech whose fiscal 2026 revenue missed its own projection by half and which carries a going-concern warning. Public holders receive non-voting stock, face heavy dilution from a variable-price preferred PIPE, and can redeem at about $12.72 per share instead.
Key Events · M&A and Partnerships · CMCAF
-
December 9 Vote on Tigerless Merger
An extraordinary general meeting is set for December 9, 2026 to approve the business combination. Holders of Founder Shares control approximately 96.6% of outstanding PVAC ordinary shares and have agreed to vote in favor, so approval is effectively assured.
-
Tigerless Misses Its Own Projections
Fiscal 2026 revenue was $780,242 versus a $1,564,377 projection, and the net loss was $654,473 versus projected net income of $162,342. On July 14, 2026, the company advised PVAC that the projections no longer reflect management's current view.
-
Going Concern and Patent-Heavy Balance Sheet
Tigerless reported a $654,473 net loss, an $858,904 accumulated deficit, a $621,860 working capital deficit and $455,942 of cash used in operations. Its $19.383 million patent portfolio, acquired from Mercury Pointe for 10 Class A shares, represents substantially all of its assets and has not been placed in service or generated revenue.
-
Variable-Price PIPE Brings Heavy Dilution Risk
Capstan Point committed $5.0 million for 5,000 Series A Preferred shares in two tranches ($3.5 million at first closing, $1.5 million on the 90th business day after closing). Conversion is at the lower of $10.00 and 93% of the five-day low VWAP with a $2.00 floor that resets lower every six months, plus 2,000,000 Closing Fee Shares transferred by existing holders.
Analysis · CMCAF · Real Estate & Construction
The definitive proxy puts a December 9 shareholder vote on taking Tigerless Health public through PVAC, and it documents a deal that has deteriorated since signing. Revenue for fiscal 2026 came in at $780,242 against a $1,564,377 projection, and the company posted a $654,473 net loss instead of the projected $162,342 profit; on July 14, 2026, management told PVAC the projections no longer reflected its view. A going-concern warning hangs over the company, and substantially all of its $19.4 million of assets is a patent portfolio acquired for 10 shares that has never been used in the business or generated revenue. The $5.0 million PIPE from Capstan Point takes the form of variable-price convertible preferred with a floor that resets lower every six months, plus 2,000,000 closing fee shares — terms that can dilute heavily if the stock falls. Public holders get non-voting Class A stock while founder Zikang Wu keeps 100% of voting power through Class B. Because the sponsor bloc controls about 96.6% of votes, approval is effectively assured regardless of public sentiment; the real decision for public holders is whether to redeem at roughly $12.72.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMCAF was trading at $13.00 on OTC in the Real Estate & Construction sector, with a market capitalization of approximately $77.4M. The 52-week trading range was $2.60 to $13.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.